The Short Answer
Retatrutide, Ozempic, and Mounjaro are three distinct molecules — not the same compound under different brand names. They are related in that all three are incretin-based metabolic research compounds acting on overlapping receptor systems, but they differ in which receptors they activate and how many. Ozempic (semaglutide) activates one receptor — GLP-1R. Mounjaro (tirzepatide) activates two — GLP-1R and GIPR. Retatrutide activates three — GLP-1R, GIPR, and the glucagon receptor (GCGR). This progression from mono to dual to triple receptor agonism represents one of the most significant trajectories in metabolic research pharmacology, and understanding the differences is essential for researchers designing incretin axis studies.
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic triple incretin receptor agonist — a single peptide molecule engineered to simultaneously activate GLP-1R, GIPR, and the glucagon receptor (GCGR). Developed by Eli Lilly, it represents the next step in the incretin agonist progression beyond tirzepatide, adding glucagon receptor activity to the existing GLP-1 and GIP dual platform. With a molecular weight of approximately 4,967 Da, retatrutide is a 36-amino acid peptide with a C20 fatty diacid modification enabling albumin binding and a once-weekly dosing profile. As of 2026, retatrutide remains in late-stage clinical development and has not received FDA approval — making research-grade retatrutide the only form available for laboratory investigation. Phase 2 clinical data published in the New England Journal of Medicine (2023) demonstrated metabolic outcomes that substantially exceeded those of both semaglutide and tirzepatide at comparable timepoints, generating intense research interest in its triple receptor mechanism. For a comprehensive mechanistic overview see our Retatrutide Research Overview.
The Three Receptors: What Each One Does
GLP-1 Receptor (GLP-1R) — Shared by All Three Compounds
GLP-1R is expressed in pancreatic beta cells, the CNS hypothalamus, gastrointestinal tract, heart, and kidney. GLP-1R activation drives glucose-dependent insulin secretion, suppresses glucagon from pancreatic alpha cells, slows gastric emptying, activates hypothalamic satiety circuits, and produces cardiovascular protective effects. This is the shared mechanistic foundation of all three compounds — semaglutide, tirzepatide, and retatrutide all engage GLP-1R, which is why all three produce improvements in glycemic control and body weight. The GLP-1R component is the best-characterized receptor in the incretin class with the most extensive clinical validation, anchoring the biological activity of all three compounds to a common, well-understood foundation.
GIP Receptor (GIPR) — Added by Tirzepatide and Retatrutide
GIPR is expressed in pancreatic beta and alpha cells, adipose tissue, bone, the GI tract, and the CNS. GIP receptor activation enhances insulin secretion through complementary but mechanistically distinct pathways from GLP-1R activation — the two receptors use different G protein coupling nuances despite both being Gs-coupled, and their distinct intracellular signaling environments in the same cell types produce non-redundant effects. In adipose tissue specifically, GIPR activation influences lipid storage, lipolysis, and adipokine secretion in ways that GLP-1R agonism alone cannot achieve — and this adipose GIPR activity is hypothesized to contribute substantially to tirzepatide’s body composition effects that appear to exceed semaglutide’s. Adding GIPR to GLP-1R agonism — as both tirzepatide and retatrutide do — engages these complementary adipose and pancreatic mechanisms simultaneously.
Glucagon Receptor (GCGR) — Added Only by Retatrutide
The glucagon receptor is what mechanistically distinguishes retatrutide from everything that came before it. GCGR is expressed in the liver, adipose tissue, heart, kidney, and brain. Glucagon is classically understood as the counter-regulatory hormone to insulin — raising blood glucose through hepatic glycogenolysis and gluconeogenesis. In isolation, glucagon receptor activation would be counterproductive in metabolic disease research. However, in the context of simultaneous GLP-1R and GIPR agonism — which provide robust insulin secretion and glucagon suppression — GCGR agonism can be co-administered without the hyperglycemic concerns it would produce alone. The specific benefit of adding GCGR agonism in this context is thermogenic: glucagon receptor activation in brown adipose tissue and liver increases energy expenditure through thermogenesis and hepatic fat oxidation — mechanisms not engaged by GLP-1R or GIPR agonism alone. This thermogenic addition is the key research rationale for the triple agonist approach and the primary hypothesis for why retatrutide’s Phase 2 metabolic data exceeded tirzepatide’s.
How Retatrutide Differs from Ozempic and Mounjaro in Research
Mechanistic Scope
Semaglutide (Ozempic) is a single-receptor reference tool — it establishes the GLP-1R-specific contribution to any observed effect. Tirzepatide (Mounjaro) adds GIPR and enables receptor subtraction studies — comparing tirzepatide vs semaglutide isolates the GIPR contribution. Retatrutide adds GCGR and enables further receptor subtraction — comparing retatrutide vs tirzepatide isolates the GCGR contribution. This three-compound toolkit allows systematic mechanistic dissection of which metabolic outcomes are attributable to GLP-1R alone, which require GLP-1R + GIPR co-activation, and which require all three receptors simultaneously. This is the most powerful experimental approach available for incretin receptor pharmacology research.
Hepatic and Thermogenic Research Applications
Retatrutide’s GCGR component opens research applications that are completely inaccessible with semaglutide or tirzepatide. Hepatic fat metabolism — relevant to NAFLD, NASH, and metabolic-associated steatohepatitis research — is heavily influenced by glucagon receptor signaling, and the GCGR component of retatrutide provides a research handle on hepatic lipid metabolism that GLP-1R and GIPR agonism alone cannot provide. Thermogenesis in brown and beige adipose tissue — relevant to energy expenditure and metabolic flexibility research — is similarly GCGR-influenced. Researchers investigating these specific biology areas will find retatrutide a uniquely capable research tool.
Clinical Development Status
A critical practical difference: semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are FDA-approved drugs. Retatrutide is not — it is in late-stage clinical development. This means research-grade retatrutide is not an alternative to a branded pharmaceutical; it is a research tool for investigating a mechanism that has no approved drug equivalent. Researchers studying triple receptor agonism have no option other than research-grade retatrutide for preclinical and in vitro investigation.
The Full Incretin Research Toolkit at AminoForge
AminoForge carries the complete incretin receptor agonism research toolkit — enabling systematic receptor progression studies from single to triple agonism:
- Semaglutide — GLP-1R monoagonist. FDA-approved as Ozempic and Wegovy. GLP-1R reference standard. Shop Semaglutide → See: Semaglutide vs Ozempic vs Wegovy
- Tirzepatide — GLP-1R + GIPR dual agonist. FDA-approved as Mounjaro and Zepbound. Shop Tirzepatide → See: Tirzepatide vs Mounjaro vs Zepbound
- Retatrutide — GLP-1R + GIPR + GCGR triple agonist. In clinical development, not yet approved. Shop Retatrutide →
- Cagrilintide — Amylin receptor agonist. Complementary non-incretin metabolic pathway. Shop Cagrilintide → See: Cagrilintide Research Overview
For a systematic comparison of the incretin research landscape and guidance on selecting the right compound for specific research questions, see our Tirzepatide Research Overview which includes a detailed three-compound comparison table. For the mechanistic rationale behind the triple agonist approach specifically, see our Retatrutide Research Overview. For further reading on retatrutide’s triple receptor mechanism see: Retatrutide triple receptor agonism and metabolic effects in Phase 2 (PubMed).
Shop Retatrutide at AminoForge — ≥99% purity, COA verified, USA manufactured, ships within 48 hours.
All products sold by AminoForge are intended exclusively for laboratory and research purposes. Not for human or veterinary consumption. Researchers are responsible for compliance with all applicable laws and regulations governing research compound use in their jurisdiction.